IM-19 is under clinical development by Beijing Immunochina Pharmaceuticals and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IM-19’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IM-19 overview

IM-19 is under development for the treatment of relapsed or refractory B-cell acute  lymphoblastic leukemia, B-cell acute lymphocytic leukemia (B-ALL), relapsed or refractory non-Hodgkin's lymphoma, B-cell chronic lymphocytic leukemia (B-CLL), diffuse large b-cell lymphoma, follicular lymphoma, primary mediastinal b-cell lymphoma and mantle cell lymphoma. The drug candidate is administered intravenously. It is developed based on chimeric antigen receptor (CAR) T-cell technology.

Beijing Immunochina Pharmaceuticals overview

Beijing Immunochina Pharmaceuticals (Immunochina) develops chimeric antigen receptor (CAR-T) cell molecules for the treatment of cancer. The company’s pipeline products include IM19, IM21, INS21(InstanCART), IM83, IM18, IM92, IM96. Its pipeline candidates treat diffuse large B cell lymphoma, B-cell acute lymphoblastic leukemia, mantle cell lymphoma (MCL), multiple myeloma, hepatocellular carcinoma, melanoma, gastric cancer & pancreatic cancer and carcinoma of colon and rectum. Immunochina utilizes its proprietary CAR-T technology platform to develop novel CAR-T therapeutics. Immunochina is headquartered in Beijing, China.

For a complete picture of IM-19’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.